Results

eNauka >  Rezultati >  Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA)
Naziv: Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA)
Autori : Trukhin, Dmytro; ...; Andric, Zoran G  ; ...; (broj, koautora 19)
Godina: 2021
Publikacija: BIODRUGS
ISSN: 1173-8804 Biodrugs Pretraži identifikator
Tip rezultata: Naučni članak
Kolacija: vol. 35 br. 4 str. 429-444
DOI: 10.1007/s40259-021-00483-w
WoS-ID: 000645472300001
Scopus-ID: 2-s2.0-85105493364
PMID: 33914256
PMCID: PMC8295170
URI: https://enauka.gov.rs/handle/123456789/799127
Projekat: mAbxience Research SL
Izvor metapodataka: (Preuzeto iz Nasi u WoS)
M-kategorija: 
21aM21a - Vodeći međunarodni časopis kategorije M21a

27
SCOPUSTM
20
PubMed CentralTM
5
OpenCitations
22
WEB OF SCIENCETM
Altmetric
Dimensions
Unpaywall

Items in eNauka are protected by copyright, with all rights reserved, unless otherwise indicated.